Clinical Trials Arena9h
Sotatercept FAERS study highlights emerging safety signals in PAH treatment
At ACC 2025, new real-world safety data were presented on sotatercept, a novel fusion protein for pulmonary arterial ...
Le Lézard1h
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
Travere Therapeutics, Inc., today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring ...
Fierce Pharma8h
Merck's Winrevair slashes mortality-morbidity risk by 76%
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Raised by Teacher Retirement System of Texas
Teacher Retirement System of Texas boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by ...